Subtype
Colon Adenocarcinoma
CI-CAN-00007498Explore in graph →
28 active trials1 approved drugs7 evidence items
- NCIt
- C4349
- OncoTree
- COAD
- DOID
- 234
- UMLS CUI
- C0338106
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00007498Explore in graph →
Clinical trials
132 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (22)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01606124 | Polyphenon E in Treating Patients With High-Risk of Colorectal Cancer | terminated | Phase 2 | 39 | Mayo ClinicOTHER | 1 | Oct 27, 2017 | clinicaltrials |
| NCT01726296 | Adherence to Survivorship Care Guidelines in Health Care Providers for Non-Small Cell Lung Cancer and Colorectal Cancer Survivor Care | completed | N/A | 1,440 | Fox Chase Cancer CenterOTHER | 1 | Apr 6, 2017 | clinicaltrials |
| Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer |
| withdrawn |
| Phase 2 |
| 0 |
| National Cancer Institute (NCI)NIH |
| 1 |
| Apr 4, 2017 |
| clinicaltrials |
| NCT02046538 | Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer | withdrawn | Phase 2 | 0 | Weill Medical College of Cornell UniversityOTHER | 1 | Jan 25, 2017 | clinicaltrials |
| NCT02575508 | Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | May 20, 2016 | clinicaltrials |
| NCT01703910 | Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic | completed | Phase 2 | 29 | Centro Nacional de Investigaciones Oncologicas CARLOS IIIOTHER | 1 | Oct 9, 2015 | clinicaltrials |
| NCT00397384 | Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer | completed | Phase 1 | 43 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2015 | clinicaltrials |
| NCT00100841 | Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer | completed | Phase 2 | 66 | National Cancer Institute (NCI)NIH | 1 | Jul 27, 2015 | clinicaltrials |
| NCT01294826 | Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer | completed | Phase 1 | 20 | Swedish Medical CenterOTHER | 1 | Jun 8, 2015 | clinicaltrials |
| NCT01198535 | Phase I Study of Cetuximab With RO4929097 in Metastatic Colorectal Cancer | terminated | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | May 18, 2015 | clinicaltrials |
| NCT02235324 | Ziv-Aflibercept Followed by Ziv-Aflibercept, Fluorouracil, and Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer | withdrawn | Phase 2 | 0 | University of Southern CaliforniaOTHER | 1 | May 6, 2015 | clinicaltrials |
| NCT00032110 | Erlotinib in Treating Patients With Recurrent or Metastatic Colorectal Cancer | completed | Phase 2 | 30 | National Cancer Institute (NCI)NIH | 1 | Apr 15, 2015 | clinicaltrials |
| NCT00551421 | Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer | completed | Phase 1 / Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Mar 31, 2015 | clinicaltrials |
| NCT00433576 | Resveratrol in Treating Patients With Colorectal Cancer That Can Be Removed By Surgery | completed | Phase 1 | 20 | National Cancer Institute (NCI)NIH | 1 | Sep 15, 2014 | clinicaltrials |
| NCT00942266 | Vorinostat, Fluorouracil, and Leucovorin Calcium in Treating Patients With Metastatic Colorectal Cancer That Has Not Responded to Previous Treatment | completed | Phase 2 | 58 | Roswell Park Cancer InstituteOTHER | 1 | Jun 23, 2014 | clinicaltrials |
| NCT00835679 | Cetuximab and/or Dasatinib in Patients With Colorectal Cancer and Liver Metastases That Can Be Removed by Surgery | terminated | Early Phase 1 | 9 | National Cancer Institute (NCI)NIH | 1 | May 23, 2014 | clinicaltrials |
| NCT01403103 | Cholecalciferol(25-[OH]-Vitamin D) in Treating Patients With Colorectal Cancer | withdrawn | Early Phase 1 | 0 | Case Comprehensive Cancer CenterOTHER | 0 | Jan 17, 2014 | clinicaltrials |
| NCT00003835 | Combination Chemotherapy in Treating Patients With Stage III Colon Cancer | completed | Phase 3 | 1,260 | National Cancer Institute (NCI)NIH | 1 | Oct 8, 2013 | clinicaltrials |
| NCT00060411 | A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal Cancer | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00026234 | Hepatic Arterial Infusion Plus Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver | completed | Phase 2 | 75 | National Cancer Institute (NCI)NIH | 1 | Jul 16, 2013 | clinicaltrials |
| NCT00003486 | Antineoplaston Therapy in Treating Patients With Colon Cancer | withdrawn | Phase 2 | 0 | Burzynski Research InstituteOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT00707889 | Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer | completed | Phase 2 | 159 | AbbVie (prior sponsor, Abbott)INDUSTRY | 14 | May 15, 2013 | clinicaltrials |
| NCT00005036 | Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer | completed | Phase 3 | 560 | National Cancer Institute (NCI)NIH | 1 | May 3, 2013 | clinicaltrials |
| NCT00002796 | Phase I-II Study of Fluorouracil in Combination With Phenylbutyrate in Advanced Colorectal Cancer | terminated | Phase 1 / Phase 2 | 46 | National Cancer Institute (NCI)NIH | 1 | Feb 1, 2013 | clinicaltrials |
| NCT00023933 | Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Recurrent or Persistent Metastatic Colorectal Cancer | completed | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Jan 25, 2013 | clinicaltrials |
| NCT00028496 | Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer | completed | Phase 1 | 48 | National Cancer Institute (NCI)NIH | 1 | Jan 25, 2013 | clinicaltrials |
| NCT00070122 | Combination Chemotherapy and Bevacizumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Colorectal Cancer | terminated | Phase 3 | 2,200 | National Cancer Institute (NCI)NIH | 1 | Jan 25, 2013 | clinicaltrials |
| NCT00003873 | Fluorouracil With or Without Eniluracil in Treating Patients With Advanced Colorectal Cancer | completed | Phase 3 | 950 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00025337 | Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously Treated | completed | Phase 3 | 880 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00005818 | SU5416 and Irinotecan in Treating Patients With Advanced Colorectal Cancer | completed | Phase 1 / Phase 2 | 68 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00052585 | Gefitinib and Combination Chemotherapy in Treating Patients With Advanced or Recurrent Colorectal Cancer | terminated | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00514332 | Comparison Between Colorectal Stents and Primary Surgery in Obstructive Colonic Cancer. A Randomized, Controlled Study | terminated | N/A | 70 | University Hospital, MontpellierOTHER | 0 | Aug 9, 2007 | clinicaltrials |
Data updated 23 days agoSource updated Oct 27, 2017source: clinicaltrials